Acid inhibition on the first day of dosing: Comparison of four proton pump inhibitors

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 12, 2003, Pages 1507-1514

  Pantoflickova, D ^a   Dorta, G ^a   Ravic, M ^b   Jornod, P ^a   Blum, A L ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; STOMACH SECRETION INHIBITOR;

ACIDITY; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG POTENCY; HELICOBACTER PYLORI; HUMAN; NORMAL HUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; ANTACIDS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; SULFOXIDES; TIME FACTORS;

EID: 0038235670     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01496.x     Document Type: Article

References (37)

1. Bell NJ, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
2. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
3. Pipkin GA, Mills JG. Onset of action of antisecretory drugs: beneficial effects of a rapid increase in intragastric pH in acid reflux disease. Scand J Gastroenterol Suppl 1999; 230: 3-8.
4. Sjostedt S, Sagar M, Lindberg G, Wikstrom B, Nord CE, Seensalu R. Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. Scand J Gastroenterol 1998; 33: 39-43.
5. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22 438-46.
6. Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998; 56: 57-70.
7. Röhss K, Hasselgren G, Hendenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-8.
8. Bruley Des Varannes S, Levy P, Lartigue S, Dellatolas F, Lemaire M, Galmiche JP. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers. Aliment Pharmacol Ther 1994; 8: 309-14.
9. Dammann HG, Fuchs W, Richter G, Burkhardt F, Wolf N, Walter TA. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Aliment Pharmacol Ther 1997; 11: 359-64.
10. Newton M, Burnham WR, Kamm MA. Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. Eur J Gastroenterol Hepatol 1998; 10: 753-8.
11. Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol 1999; 34: 341-5.
12. Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric pH. J Clin Gastroenterol 1997; 24: 65-70.
13. Dammann HG, Burkhardt F. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion. Eur J Gastroenterol Hepatol 1999; 11: 1277-82.
14. Hartmann M, Theiss U, Huber R, et al. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole. Aliment Pharmacol Ther 1996; 10: 359-66.
15. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
16. Huang JQ, Goldwater DR, Thomson AB, et al. Acid suppression in healthy subjects following lansoprazole or pantoprazole. Aliment Pharmacol Ther 2002; 16: 425-33.
17. Meier R, Wolf A, Wettstein A, Drewe J, Messmer H. The effect of a single dose of a proton pump inhibitor on gastric acidity in volunteers. Gut 2000; 47(Suppl. 3): A81(Abstract).
18. Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 455-64.
19. Bauerfeind A, Cilluffo T, Emde C. Antacids revisited: how do they react with food in vivo? Gastroenterology 1986; 90: 1340.
20. Brummer RJ, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci 1997; 42: 2132-7.
21. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. PPIs: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000; 14: 1267-72.
22. Bergstrand R, Grind M, Nyberg G, Olofsson B. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 1995; 9: 67-71.
23. Logan RP. Urea breath tests in the management of Helicobacter pylori infection. Gut 1998; 43(Suppl. 1): S47-50.
24. Pilbrant A. Pharmaceutical considerations. In: Olbe L, ed. Proton Pump Inhibitors. Basle: Birkhaus. 2001: 161-72.
25. Saitoh T, Watanabe Y, Kubo Y, et al. Intragastric acidity and circadian rhythm. Biomed Pharmacother 2001; 55(Suppl. 1): 138s-141s.
26. Baisley K, Warrington S, Tejura B, Morocutti A, Miller N. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers. Gut 2002; 50(Suppl. ii): A63(Abstract 229).
27. Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002; 16: 1301-7.
28. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in management of acid-related disorders. Drugs 2002; 62: 1503-38.
29. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-7.
30. Landes BD, Petite JP, Fluovat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458-70.
31. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34: 185-94.
32. Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411-26.
33. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 907-14.
34. Earnest DL, Robinson M. Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution. Am J Gastroenterol 1999; 94(Suppl. 11): S17-24.
35. Barth J, Hahne W. Rabeprazole-based therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2002; 16(Suppl. 1): 31-3.
36. Hawkey C, Atherton J, Treichel H, et al. Rabeprazole vs. omeprazole in 7-day, triple therapy H. pylori eradication regimens for peptic ulcer. Gastroenterology 2001; 120: 581(Abstract).
37. Vakil N, Schwartz HJ, Lanza FL, et al. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA. Gastroenterology 2002; 122: 551(Abstract).